Panoply™ Human SMARCA4 Knockdown Stable Cell Line

The tumor suppressor gene SMARCA4 is a key component of the SWI/SNF chromatin remodeling complex and is frequently inactivated in various cancers, including clear cell renal cell carcinoma (ccRCC). Despite its importance, the role of SMARCA4 in the development and progression of ccRCC and its potential therapeutic targets remain largely unexplored. Here, researchers found that SMARCA4 deficiency is associated with poor prognosis and is observed in some high-grade ccRCC. Through functional analysis, they determined that inhibition of SMARCA4 leads to increased RCC cell proliferation. Further gene expression analysis revealed that SMARCA4-deficient cells exhibit upregulation of the oxidative phosphorylation (OXPHOS) pathway. Furthermore, SMARCA4-deficient RCC cells and xenografts showed greater sensitivity to inhibition of the OXPHOS pathway by the novel small molecule IACS-010759. This sensitivity is attributed to the higher energy demand and sensitivity to energy stress observed in SMARCA4-deficient cells, which are driven by their enhanced biosynthetic needs.

Here, researchers constructed a SMARCA4 knockdown cell line. The results showed enhanced cell proliferation, invasion, and migration in SMARCA4-knockdown ACHN and 786-O cells (Figure 1). In summary, these findings highlight the indispensable role of SMARCA4 in regulating the tumorigenic and metastatic behavior of renal cell carcinoma (RCC) cells, underscoring its potential as a key therapeutic target for clear cell renal cell carcinoma (ccRCC).

Figure 1. SMARCA4 knockdown enhanced the proliferation, invasion, and migration abilities of ACHN and 786-O cells. (Fang, Ru, et al., 2025)